155
Participants
Start Date
November 5, 2021
Primary Completion Date
January 31, 2026
Study Completion Date
June 30, 2027
Debio 0123
Debio 0123 orally during 21-day treatment cycles.
RECRUITING
Inselspital, Universitaetsspital Bern, Freiburgstrasse 4, Bern
RECRUITING
Istituto Oncologico della Svizzera italiana - Ente Ospedaliero Cantonale, Bellinzona
COMPLETED
Universitätsspital Zürich, Dermatologische Klinik, Zurich
RECRUITING
Kantonsspital St. Gallen, Rorschacher Strasse 95, Sankt Gallen
RECRUITING
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Hospital Universitario de A Coruna, A Coruña
RECRUITING
Institut Catala de Oncologia, Girona
RECRUITING
Clinica Universidad de Navarra, Madrid
RECRUITING
START Madrid. Hospital Fundación Jimenez Diaz, Madrid
RECRUITING
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
Hospital Universitario La Paz, Madrid
RECRUITING
Clinica Universidad de Navarra, Pamplona
RECRUITING
Hospital Clinico Universitario de Valencia, Valencia
RECRUITING
South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
RECRUITING
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
RECRUITING
South Texas Accelerated Research Therapeutics (START), San Antonio
RECRUITING
Hospital Universitari Vall d'Hebron, Barcelona
Lead Sponsor
Debiopharm International SA
INDUSTRY